ARGX 111Alternative Names: Anti-cMet SIMPLE Antibody; ARGX-111
Latest Information Update: 19 Feb 2016
At a glance
- Originator arGEN-X
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Proto oncogene protein c met inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I Solid tumours